Printer Friendly
The Free Library
19,585,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioSphere Medical To Announce 3rd Quarter, 2004 Earnings Results.


ROCKLAND, Mass. -- BIOSPHERE MEDICAL, (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:BSMD), the medical device company that pioneered the use of bioengineered microspheres to treat hypervascularized tumors, vascular malformations and uterine fibroids Uterine Fibroids Definition

Uterine fibroids (also called leiomyomas or myomas) are benign growths of the muscle inside the uterus. They are not cancerous, nor are they related to cancer.
, by occluding their blood supply, announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, November 4th at 11:00 a.m. Eastern Time (10 a.m. Central Time).

The number to dial into the teleconference is (719) 457-2664. Please call in approximately ten minutes before the call is scheduled to begin. The call is being webcast by CCBN CCBN Central Coast Bancorp
CCBN Charles County Business Network
 and can be accessed at our web site: www.biospheremed.com.

A replay of the teleconference will be available from 2:30 P.M. (ET) Thursday, November 4th until 12:00 A.M. (ET) on November 11th, 2004. The replay dial-in number is: (719) 457-0820. The Access Code is 887898. A replay of the webcast will be available in the investor section of our company website at www.biospheremed.com.

About BioSphere Medical, Inc.

BioSphere Medical, Inc., based in Rockland, Massachusetts, is a medical device company focused on applying our proprietary microsphere Not to be confused with Glass microphere.
This article largely refers to micropheres or protein protocells as small spherical units postulated by some scientists as a key stage in the origin of life.
 technology to medical applications using embolotherapy techniques. Our core technologies, patented bio-engineered polymers and manufacturing methods, are used to produce miniature spherical beads with uniquely beneficial properties for a variety of medical applications. Our principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization Uterine Fibroid Embolization Definition

Uterine fibroids are growths in the muscular tissue of the womb (uterus). Uterine fibroid embolization is non-surgical removal of the growths through the use of a tubular device called a catheter.
, or UFE UFE Uterine Fibroid Embolization
UFE United for a Fair Economy
UFE Ufficio Federale dell'Energia
UFE Uniform Final Examination
UFE Urban Challenge Final Event (DARPA)
UFE Unidentified Flags and Ensigns
UFE Unrestricted Free Agent
.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 8, 2004
Words:236
Previous Article:NMDA Finalizes Partnership with Wildside Software; Recruitment of Motorcycle Rental Operators On Target; MBAH to Limit Issuance of Shares on Open...
Next Article:Viasystems Group, Inc. Closes Rights Offering and Standby Commitment Agreement.



Related Articles
Life Energy & Technology Holdings Inc. files Quarterly Report.
BioSphere Medical Reports Fourth Quarter and Fiscal Year 2003 Financial Results.
BioSphere Medical To Announce 1st Quarter, 2004 Earnings Results.
BioSphere Medical To Announce 2nd Quarter, 2004 Earnings Results.
BioSphere Medical Reports Second Quarter 2004 Financial Results.
BioSphere Medical Appoints Richard J. Faleschini As CEO.
BioSphere Medical Reports Third Quarter 2004 Financial Results; Total Revenue Up 16%; Net Loss Decreased 21% from Prior Year Period.
BioSphere Medical Announces Court's Decision in Contract Claim Brought by Terumo Europe N.V.; BioSphere's French subsidiary required to pay...
BioSphere Medical Reports Fourth Quarter and Full Year 2004 Financial Results.
BioSphere Medical to Present at Rodman and Renshaw 3rd Annual Global Healthcare Conference.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles